Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 4:05 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | D. E. SHAW & CO L.P. | 764,613 3.500% | 44,240 (+6.14%) | Filing History |
| 2022-02-14 3:04 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Cormorant Asset Management LP | 1,436,322 6.280% | 1,436,322 (New Position) | Filing History |
| 2022-02-14 2:47 pm Sale | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Logos Global Management LP | 0 0.000% | -1,495,000 (Position Closed) | Filing History |
| 2022-02-14 1:51 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | BIOTECHNOLOGY VALUE FUND L P | 2,202,315 9.990% | 2,202,315 (New Position) | Filing History |
| 2022-02-14 06:19 am Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | CITADEL ADVISORS LLC | 943,340 4.300% | 943,340 (New Position) | Filing History |
| 2022-02-14 06:12 am Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 1,209,051 5.570% | 1,209,051 (New Position) | Filing History |
| 2022-02-11 4:19 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Ally Bridge MedAlpha Master Fund L.P. | 604,774 2.800% | 604,774 (New Position) | Filing History |
| 2022-02-04 08:01 am Sale | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Hawkes Bay Master Investors (Cayman) L.P. | 0 0.000% | -363,284 (Position Closed) | Filing History |
| 2022-01-28 1:39 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Frazier Life Sciences Public Fund L.P. | 1,505,200 6.900% | 200,000 (+15.32%) | Filing History |
| 2021-10-27 6:12 pm Purchase | 2021-10-21 | 13G | Viridian Therapeutics, Inc. VRDN | Avidity Partners Management LP | 1,120,925 6.600% | 1,120,925 (New Position) | Filing History |
| 2021-10-14 4:05 pm Purchase | 2021-10-04 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III L.P. | 1,943,055 9.990% | 1,943,055 (New Position) | Filing History |
| 2021-10-08 08:36 am Sale | 2021-09-30 | 13G | Viridian Therapeutics, Inc. VRDN | WELLINGTON MANAGEMENT GROUP LLP | 0 0.000% | -578,560 (Position Closed) | Filing History |
| 2021-09-30 4:30 pm Purchase | 2021-09-21 | 13G | Viridian Therapeutics, Inc. VRDN | Vivo Opportunity LLC | 1,300,000 7.700% | 1,300,000 (New Position) | Filing History |
| 2021-09-29 09:30 am Purchase | 2021-09-21 | 13G | Viridian Therapeutics, Inc. VRDN | Logos Global Management LP | 1,495,000 8.800% | 1,495,000 (New Position) | Filing History |
| 2021-09-29 06:02 am Unchanged | 2021-09-23 | 13G | Viridian Therapeutics, Inc. VRDN | TCG Crossover Management LLC | 1,314,000 8.200% | 0 (Unchanged) | Filing History |
| 2021-09-24 5:01 pm Purchase | 2021-09-21 | 13G | Viridian Therapeutics, Inc. VRDN | Deep Track Capital LP | 1,819,689 9.900% | 1,819,689 (New Position) | Filing History |
| 2021-09-24 1:59 pm Purchase | 2021-09-21 | 13G | Viridian Therapeutics, Inc. VRDN | TCG Crossover Management LLC | 1,314,000 13.700% | 400,000 (+43.76%) | Filing History |
| 2021-09-23 4:31 pm Purchase | 2021-09-21 | 13D | Viridian Therapeutics, Inc. VRDN | Fairmount Funds Management LLC | 3,460,351 19.990% | 3,460,351 (New Position) | Filing History |
| 2021-09-10 06:03 am Purchase | 2021-09-01 | 13G | Viridian Therapeutics, Inc. VRDN | TCG Crossover Management LLC | 914,000 9.500% | 914,000 (New Position) | Filing History |
| 2021-08-26 12:56 pm Purchase | 2021-08-16 | 13G | Viridian Therapeutics, Inc. VRDN | Frazier Life Sciences Public Fund L.P. | 1,305,200 13.600% | 1,305,200 (New Position) | Filing History |